Arcutis Biotherapeutics (ARQT) stock is in focus after the FDA accepted the company’s supplemental New Drug Application for ZORYVE cream 0.05% in infants with mild to moderate atopic dermatitis, opening a potential new pediatric segment.
See our latest analysis for Arcutis Biotherapeutics.
At a share price of $28.78, Arcutis Biotherapeutics has a 30 day share price return of 26.28% and a 1 year total shareholder return of 88.47%. This performance suggests momentum has been building as the ZORYVE label expansions and virtual health launch keep the story in the headlines.
If this kind of regulatory and product news has your attention, it can also be worth scanning other healthcare focused AI opportunities through our 40 healthcare AI stocks
After a rapid move higher and fresh excitement around ZORYVE’s pediatric reach and virtual health push, the real issue for Arcutis Biotherapeutics now is simple: does the current price still leave enough upside to justify the risks?
Most Popular Narrative: 28% Undervalued
Compared with Arcutis Biotherapeutics' last close at $28.78, the most followed narrative sees fair value around $40, pointing to a sizable valuation gap.
It is almost impossible to obtain a drug label from the FDA for pediatric use, this topical non-steroidal drug ZORYVE is very safe and highly effective for both pediatric and adult patients. The drug is potent in the skin, it is not well absorbed and is quickly metabolized which limits systemic exposure and minimizes side effect risks.
Want to understand why this narrative supports a higher price tag for Arcutis Biotherapeutics? It leans heavily on rapid revenue expansion, improving margins and a future earnings profile that treats dermatology like a high growth specialty. Curious which specific growth path and profitability assumptions are baked into that view? The full narrative lays out the numbers that connect ZORYVE, cash generation and that fair value in detail.
Result: Fair Value of $39.99 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on Arcutis Biotherapeutics turning current revenue of $415.624 and a net loss of $2.376 into durable profitability while managing regulatory and reimbursement setbacks.
Find out about the key risks to this Arcutis Biotherapeutics narrative.
Next Steps
If the optimism in this Arcutis Biotherapeutics story resonates, consider acting promptly and review the numbers yourself before opinions settle. To see what investors are highlighting as potential upsides, review the 5 key rewards
Looking for more investment ideas beyond Arcutis Biotherapeutics?
If Arcutis Biotherapeutics has sharpened your interest, do not stop here; the next strong idea could already be on your radar using the Simply Wall Street Screener.
- Target potential mispricing by scanning companies that look attractively valued through the 44 high quality undervalued stocks.
- Strengthen your defensive side by searching for companies highlighted in the 73 resilient stocks with low risk scores.
- Spot lesser known opportunities by reviewing the screener containing 19 high quality undiscovered gems before they are widely discussed.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com